Cohance Lifesciences is trading 2.63% upper at Rs 302.00 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 303.15 & 291.35. Cohance Lifesciences has given -44.49% in this year & 3.86% in the last 5 days. Cohance Lifesciences has TTM P/E ratio 90.64 as compared to the sector P/E of 23.34.There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 2 analysts who have given it a strong buy rating & 3 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 36.72 Crores in its last quarter.Listed peers of Cohance Lifesciences include Cipla (-1.34%), Torrent Pharmaceuticals (1.01%), Dr Reddy's Laboratories (0.51%).The Mutual Fund holding in Cohance Lifesciences was at 17.36% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Cohance Lifesciences was at 6.01% in 31 Dec 2025. The FII holding has decreased from the last quarter.
Updated on Mar 17, 2026, 04:16 PM UTC
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Bearish | 1,281.45 | -1.34 | 1,03,513.05 | 22.95 | 3.87 | 0.87 | 0.81 |
| Torrent Pharmaceuticals | Neutral | 4,305.95 | 1.01 | 1,45,727.06 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | Neutral | 1,281.55 | 0.51 | 1,06,958.67 | 18.63 | 3.14 | 0.63 | 2.34 |
| Sun Pharmaceutical Industries | Bullish | 1,790.70 | 0.46 | 4,30,738.26 | 36.24 | 5.77 | 0.92 | 0.50 |
| Divi's Laboratories | Bearish | 6,094.00 | 0.31 | 1,62,563.29 | 78.61 | 11.52 | 0.46 | 0.01 |
| Meeting Date | Purpose |
|---|---|
| 2026-02-12 | Quarterly Results |
| 2025-11-12 | Quarterly Results |
| 2025-05-28 | Audited Results |
| 2025-02-12 | Quarterly Results |
| 2024-11-12 | Quarterly Results |
Cohance Lifesciences is trading at 302.00 as on Tue Mar 17 2026 09:59:50. This is 2.63% upper as compared to its previous closing price of 294.25.
The market capitalization of Cohance Lifesciences is 11587.00 Cr as on Tue Mar 17 2026 09:59:50.
The average broker rating on Cohance Lifesciences is Buy. The breakup of analyst rating is given below -
The 52 wk high for Cohance Lifesciences is 1246.85 whereas the 52 wk low is 267.85
Cohance Lifesciences can be analyzed on the following key metrics -
Cohance Lifesciences reported a net profit of 267.87 Cr in 2025.
The Mutual Fund Shareholding was 17.36% at the end of 31 Dec 2025.